Top 5 Low Price Stocks To Buy Right Now

Click the stock to track shares of Priceline.com.

NEW YORK (CNNMoney) The most expensive stock in the S&P 500 just got even pricier. Shares of Priceline.com soared again Monday, rising to an all-time high above $1,100.

In September, Priceline (PCLN, Fortune 500) became the first S&P 500 company to hit a four-digit price. Google (GOOG, Fortune 500) became the second to achieve the milestone last month. But Google is about 10% below Priceline newest peak of $1,109.50.

Though Priceline is up nearly 80% so far this year, analysts remain bullish. The average price target on Wall Street stands above $1,200 per share, up another 10% from current levels.

While Priceline shares are not cheap, they're not terribly overvalued either for being the leader in online travel. Shares are trading around 21 times 2014 earnings estimates. That makes it more expensive than rival Expedia (EXPE), but the stock is trading at a discount compared to Orbitz (OWW) and TripAdvisor (TRIP).

Top 5 Low Price Stocks To Buy Right Now: Kulicke and Soffa Industries Inc.(KLIC)

Kulicke and Soffa Industries, Inc. designs, manufactures, and sells capital equipment and expendable tools used to assemble semiconductor devices, including integrated circuits, high and low powered discrete devices, light-emitting diodes, and power modules. It also services, maintains, repairs, and upgrades its equipment. The company operates in two segments, Equipment and Expendable Tools. The Equipment segment manufactures and sells a line of ball bonders, heavy wire wedge bonders, stud bumpers, and die bonders. Its Ball bonders are used to connect very fine wires, primarily made of gold or copper, between the bond pads of the semiconductor device or die, and the leads on its package; Heavy wire wedge bonders are used in the power semiconductor and automotive power module markets; and Die bonders are used to attach a die to the substrate or lead frame, which will house the semiconductor device. This segment?s Stud bumpers mechanically apply bumps to die, while still in the wafer format, for some variants of the flip chip assembly process. The Expendable Tools segment manufactures and sells various expendable tools for a range of semiconductor packaging applications. Its products include capillaries, bonding wedges, and saw blades. The company?s customers primarily comprise semiconductor device manufacturers, outsourced semiconductor assembly and test providers, other electronics manufacturers, and automotive electronics suppliers in the United States and the Asia/Pacific region. Kulicke and Soffa Industries sells its products through manufacturers? representatives and distributors. The company was founded in 1951 and is headquartered in Singapore.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, chip equipment maker Kulicke and Soffa Industries (NASDAQ: KLIC  ) has earned a coveted five-star ranking.

Top 5 Low Price Stocks To Buy Right Now: Fortune Oil(FTO.L)

Fortune Oil PLC, through its jointly controlled entities, focuses on investments and operations in oil and gas supply, and infrastructure projects in the People?s Republic of China. The company engages in the construction and operation of aviation oil storage and supply facilities; the storage of petroleum; the operation of jetty; the provision of piped natural gas, compressed natural gas, and transportation services; and the operation of gasoline stations. It also invests in the development of commercialization of coal bed methane gas projects primarily in Shanxi Province, as well as operates in the Liulin CBM block State Pilot Project. The company is headquartered in Wanchai, Hong Kong.

Top 5 Oil Companies To Buy Right Now: Weir Grp(WEIR.L)

The Weir Group PLC engages in minerals, oil and gas, and power and industrial businesses worldwide. Its Minerals segment designs and manufactures slurry handling equipment, including pumps, hydrocyclones, valves, and other complementary equipment primarily for the mining, flue gas desulphurization, and oil sands markets. The company?s Oil & Gas segment designs and manufactures pumps and ancillary equipment for upstream and downstream oil and gas markets, as well as engages in aftermarket service and support activities. Its Power & Industrial segment designs, manufactures, and provides aftermarket support for rotating and flow control equipment to the power sector. The company also offers equipment to the liquefied petroleum gas marine and onshore markets. The Weir Group PLC was founded in 1871 and is headquartered in Glasgow, the United Kingdom.

Top 5 Low Price Stocks To Buy Right Now: ProShares UltraShort S&P500 (SDS)

ProShares UltraShort S&P500 (the Fund), formerly UltraShort S&P500 ProShares, seeks daily investment results that correspond to twice the inverse daily performance of the S&P 500 Index. The S&P 500 Index is a measure of large-cap United States stock market performance. The S&P 500 Index is a capitalization-weighted index of 500 United States operating companies and real estate investment trusts (REITs) selected by an S&P committee through a non-mechanical process that factors criteria, such as liquidity, price, market capitalization, financial viability and public float.

The S&P 500 Index is a price return index. Reconstitution of the Index occurs both on a quarterly and on an ongoing basis. The Fund takes positions in securities and/or financial instruments that, in combination, should have similar daily return characteristics as 200% of the daily return of the index. The Fund�� investment advisor is ProShare Advisors LLC.

Advisors' Opinion:

• [By John Udovich]

  The so-called Hindenburg Omen predicting a major market crash is increasingly popping into the headlines; but regardless of whether or not you believe in the prophecy,�short ETFs like ProShares UltraShort S&P500 ETF (NYSEARCA: SDS), ProShares Short Dow30 ETF (NYSEARCA: DOG) and�ProShares UltraShort QQQ ETF (NYSEARCA: QID) can off you some protection or insurance. We have also periodically added short ETFs to our�SmallCap Network Elite Opportunity (SCN EO) portfolio as a�hedge against short-term�market downturns or�short-term trend reversals and right now, we have the ProShares UltraShort S&P500 ETF in our portfolio.

Top 5 Low Price Stocks To Buy Right Now: Raptor Pharmaceutical Corp.(RPTP)

Raptor Pharmaceuticals Corp. operates as a biotechnology company in the United States. The company is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Its clinical stage development products include DR Cysteamine, which is in phase IIb for the treatment of cystinosis; phase IIa for the non-alcoholic steatohepatitis; and phase II for the treatment of Huntington?s disease. Raptor?s clinical-stage products also include Convivia that is in Phase IIa stage for the potential management of acetaldehyde toxicity due to alcohol consumption; and Tezampanel and NGX 426, which completed phase I stage for the treatment of migraine and pain. Its preclinical product candidates comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis; WntTide for the treatment of breast cancer; NeuroTrans for the treatmen t of neurodegenerative diseases; and Tezampanel and NGX 426 for the treatment of Thrombosis and Spasticity Disorder. Raptor Pharmaceuticals Corp. is headquartered in Novato, California.

Advisors' Opinion:

• [By Roberto Pedone]

  One biotechnology player that's starting to trend within range of triggering a big breakout trade is Raptor Pharmaceuticals (RPTP), which has a pipeline that includes both candidates from its proprietary drug targeting platforms and in-licensed and acquired product candidates. This stock is in play with the bulls so far in 2013, with shares up sharply by 151%.

  >>5 Hated Earnings Stocks You Should Love

  If you take a look at the chart for Raptor Pharmaceuticals, you'll notice that stock has been uptrending strong for the last six months, with shares soaring higher from its low of $5.50 to its recent high of $15.29 a share. During that uptrend, shares of RPTP have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RPTP within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in RPTP if it manages to break out above some near-term overhead resistance levels at $14.99 a share to its 52-week high at $15.29 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 844,332 shares. If that breakout triggers soon, then RPTP will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $18 to $20 a share, or even north of $20 a share.

  Traders can look to buy RPTP off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $13.69 a share or at $13 a share. One can also buy RPTP off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Sean Williams]

  Raptor Pharmaceuticals (NASDAQ: RPTP  ) also gave shareholders something to cheer about when, on Tuesday, the company announced that the Food and Drug Administration had granted Procysbi, its nephropathic cystinosis drug, U.S. orphan drug status. Although FDA-approved drugs are protected by patent for a period of 20 years, the U.S. orphan drug status will keep biosimilar competition from competing against Raptor's Procysbi through April 30, 2020. In addition, on Friday Procysbi received a positive opinion from the European Medicine Agency's panel that the drug be recommended for approval in the EU. However, I'd caution calmer heads prevail here as the total market for the drug is only about 2,000 people worldwide and peak sales estimates in the U.S. are a mere $60 million.

• [By Sean Williams]

  Veloci-Raptor time?
  First up is Raptor Pharmaceuticals (NASDAQ: RPTP  ) with Procysbi (previously known as RP-103), its oral delayed and extended-release medication to treat nephropathic cystinosis. In trials, Procysbi proved to be non-inferior to the only other FDA-approved treatment for nephropathic cystinosis, known as Cystagon from Mylan (NASDAQ: MYL  ) .

• [By Sean Williams]

  This week saw two new drugs approved by the FDA: Raptor Pharmaceuticals' (NASDAQ: RPTP  ) Procysbi and Merck's (NYSE: MRK  ) Liptruzet.